Compass Therapeutics, Inc.
CMPX · XNASCIK 1738021fmd_0SYTSJSWGXDJTVD4A5ACCHW43RManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 35 periods
| Line item | FY2019 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 0 | 1 | 0 |
| Research and development | – | 22 | 15 | 20 | 30 | 38 | 42 | 56 |
| Total operating expenses | – | 34 | 28 | 82 | 42 | 50 | 57 | 73 |
| Operating income | (0) | – | (28) | (82) | (42) | (50) | (57) | (73) |
| Interest expense | 0 | – | 1 | 0 | 0 | – | – | – |
| Interest and investment income | – | 1 | 0 | 0 | 2 | 8 | 7 | 6 |
| Other non-operating income (expense) | – | (1) | (2) | (0) | 2 | 8 | 7 | 6 |
| Income before taxes | – | (35) | (29) | (82) | (39) | (42) | – | – |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (35) | (30) | (82) | (39) | (42) | – | – |
| Net income | – | (35) | (30) | (82) | (39) | (42) | (49) | (66) |